Breast cancer patients undergoing paclitaxel-based chemotherapy. Malignant neoplasm of breast
Conditions
Interventions
Intervention 1: Patients in the intervention group receive metformin in addition to paclitaxel chemotherapy. The prescribed dose of metformin is 1500 mg daily, administered as three 500 mg tablets thr
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Female patients with histologically confirmed breast cancer (diagnosed by biopsy) Age = 18 years Eligible for paclitaxel-based chemotherapy
Exclusion criteria
Exclusion criteria: History or presence of active diabetes mellitus Pre-existing neuropathy or neurological disorders Anemia Prior chemotherapy exposure Active thyroid disease Gastrointestinal disorders leading to poor tolerability of metformin Any contraindication for metformin administration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of chemotherapy-induced neuropathy. Timepoint: Before intervention (baseline) - Three months after intervention. Method of measurement: Neuropathy severity assessed using CTCAE and PNQ questionnaires.;Expression levels of lncRNAs MALAT1 and XIST. Timepoint: Before intervention (baseline) - Three months after intervention. Method of measurement: Gene expression measured by Real-Time PCR. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Reza Mahmoudian-Sani
Ahvaz University of Medical Sciences
Outcome results
None listed